A new migraine medication being developed by Eli Lilly and Co. hit the mark on a critical target in a recent study.
According to the company, patients who took the experimental medication, galcanezumab, experienced 8.7 fewer cluster headache attacks per week during a three-week course of the treatment. Patients receiving a placebo experience 5.2 fewer headache attacks during the same time. On average, patients in the study experience 17.5 episodic cluster headaches each week.
Migraines are still very difficult to treat and many companies have been racing to develop a new class of drugs that zero in on a protein called calcitonin gene-related peptide (CGRP), which is involved in signaling pain. Several other companies have CGRP drugs in the pipeline, but Amgen may have its highly anticipated new migraine treatment — Aimovig — approved by the FDA as early as this week.
Read the full Reuters report.